Side effects include galactorrhea, gynecomastia, or menstrual irregularities.
A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Deferasirox | The serum concentration of Domperidone can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Domperidone can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Domperidone can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Domperidone can be decreased when it is combined with Teriflunomide. |
| Mifepristone | The serum concentration of Domperidone can be increased when it is combined with Mifepristone. |
| Linezolid | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Linezolid is combined with Domperidone. |
| Furazolidone | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Furazolidone is combined with Domperidone. |
| Procaine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Procaine is combined with Domperidone. |
| Tranylcypromine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Tranylcypromine is combined with Domperidone. |
| Phenelzine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Phenelzine is combined with Domperidone. |
| Minaprine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Minaprine is combined with Domperidone. |
| Selegiline | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Selegiline is combined with Domperidone. |
| Procarbazine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Procarbazine is combined with Domperidone. |
| Moclobemide | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Moclobemide is combined with Domperidone. |
| Isocarboxazid | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Isocarboxazid is combined with Domperidone. |
| Rasagiline | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Rasagiline is combined with Domperidone. |
| Pargyline | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Pargyline is combined with Domperidone. |
| Clorgiline | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Clorgiline is combined with Domperidone. |
| Iproniazid | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Iproniazid is combined with Domperidone. |
| Nialamide | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Nialamide is combined with Domperidone. |
| Safinamide | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Safinamide is combined with Domperidone. |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Domperidone. |
| Methylene blue | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Methylene blue is combined with Domperidone. |
| Hydracarbazine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Hydracarbazine is combined with Domperidone. |
| Pirlindole | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Pirlindole is combined with Domperidone. |
| Toloxatone | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Toloxatone is combined with Domperidone. |
| Benmoxin | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Benmoxin is combined with Domperidone. |
| Mebanazine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Mebanazine is combined with Domperidone. |
| Octamoxin | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Octamoxin is combined with Domperidone. |
| Pheniprazine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Pheniprazine is combined with Domperidone. |
| Phenoxypropazine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Phenoxypropazine is combined with Domperidone. |
| Pivhydrazine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Pivhydrazine is combined with Domperidone. |
| Safrazine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Safrazine is combined with Domperidone. |
| Caroxazone | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Caroxazone is combined with Domperidone. |
| Harmaline | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Harmaline is combined with Domperidone. |
| Brofaromine | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Brofaromine is combined with Domperidone. |
| Mirabegron | The serum concentration of Domperidone can be increased when it is combined with Mirabegron. |
| Abiraterone | The serum concentration of Domperidone can be increased when it is combined with Abiraterone. |
| Cyproterone acetate | The metabolism of Domperidone can be increased when combined with Cyproterone acetate. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Domperidone. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Domperidone. |
| Erythromycin | The serum concentration of Domperidone can be increased when it is combined with Erythromycin. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Domperidone. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Domperidone. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Domperidone. |
| Methadone | The risk or severity of QTc prolongation can be increased when Methadone is combined with Domperidone. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Domperidone. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Domperidone. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Domperidone. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Domperidone. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Domperidone. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Domperidone. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Domperidone. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Domperidone. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Domperidone. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Domperidone. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Domperidone. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Domperidone. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Domperidone. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Domperidone. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Domperidone. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Domperidone. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Domperidone. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Domperidone. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Domperidone. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Domperidone. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Domperidone. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Domperidone. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Domperidone. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Domperidone. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Domperidone. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Domperidone. |
| Nifedipine | The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Domperidone. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Domperidone. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Domperidone. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Domperidone. |
| Mibefradil | The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Domperidone. |
| Probucol | The risk or severity of QTc prolongation can be increased when Probucol is combined with Domperidone. |
| Aceprometazine | The risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Domperidone. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Domperidone. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Domperidone. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Domperidone. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Domperidone. |
| Azimilide | The risk or severity of QTc prolongation can be increased when Azimilide is combined with Domperidone. |
| Pracinostat | The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Domperidone. |
| Technetium Tc-99m ciprofloxacin | The risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Domperidone. |
| Garenoxacin | The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Domperidone. |
| Tedisamil | The risk or severity of QTc prolongation can be increased when Tedisamil is combined with Domperidone. |
| Tucidinostat | The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Domperidone. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Telavancin is combined with Domperidone. |
| Nemonoxacin | The risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Domperidone. |
| Nilvadipine | The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Domperidone. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Antazoline is combined with Domperidone. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Domperidone is combined with Bedaquiline. |
| Fendiline | The risk or severity of QTc prolongation can be increased when Fendiline is combined with Domperidone. |
| Eperisone | The risk or severity of QTc prolongation can be increased when Eperisone is combined with Domperidone. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Domperidone. |
| Ceritinib | The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Domperidone. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Domperidone. |
| Melperone | The risk or severity of QTc prolongation can be increased when Melperone is combined with Domperidone. |